Stoke Therapeutics, Inc. (STOK)Healthcare | Biotechnology | Bedford, United States | NasdaqGS
36.46 USD
-0.81
(-2.173%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:18 a.m. EDT
Despite weak fundamentals (revenue down ~94%, negative cash flow), short-term technicals and insider sentiment support a cautious buy. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.093883 |
| AutoARIMA | 0.130735 |
| AutoETS | 0.131580 |
| MSTL | 0.132268 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.78 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.284 |
| Excess Kurtosis | -0.43 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.177 |
| Revenue per Share | 3.114 |
| Market Cap | 2,156,637,696 |
| Forward P/E | -11.48 |
| Beta | 1.22 |
| Profit Margins | -3.73% |
| Website | https://www.stoketherapeutics.com |
As of April 19, 2026, 12:18 a.m. EDT: Speculator positioning is dominated by calls at the $45 strike (MC 255 vol, significant new flow), indicating a bullish expectation of a move higher from the current ~$37. Put activity is defensive, concentrated at the $30 strike (warranted for downside fear near the $30 support level), implying the market views $30 as a key support level for the near-term (May expiry). Implied volatility is skewed higher for puts (1.01 ATM) compared to calls (0.76 ATM), suggesting asymmetric risk perception but a net directional play for upside.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.9544468 |
| Address1 | 45 Wiggins Avenue |
| All Time High | 71.58 |
| All Time Low | 3.35 |
| Ask | 36.51 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 627,080 |
| Average Daily Volume3 Month | 752,075 |
| Average Volume | 752,075 |
| Average Volume10Days | 627,080 |
| Beta | 1.221 |
| Bid | 36.34 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 5.982 |
| City | Bedford |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 36.46 |
| Current Ratio | 5.282 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 37.28 |
| Day Low | 35.86 |
| Debt To Equity | 1.177 |
| Display Name | Stoke Therapeutics |
| Earnings Call Timestamp End | 1,762,291,800 |
| Earnings Call Timestamp Start | 1,762,291,800 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -18,820,000 |
| Ebitda Margins | -0.10205 |
| Enterprise To Ebitda | -99.687 |
| Enterprise To Revenue | 10.173 |
| Enterprise Value | 1,876,115,840 |
| Eps Current Year | -3.368 |
| Eps Forward | -3.17667 |
| Eps Trailing Twelve Months | -0.12 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 34.1606 |
| Fifty Day Average Change | 2.2994003 |
| Fifty Day Average Change Percent | 0.06731147 |
| Fifty Two Week Change Percent | 295.44467 |
| Fifty Two Week High | 40.22 |
| Fifty Two Week High Change | -3.7600021 |
| Fifty Two Week High Change Percent | -0.09348588 |
| Fifty Two Week Low | 8.3 |
| Fifty Two Week Low Change | 28.16 |
| Fifty Two Week Low Change Percent | 3.392771 |
| Fifty Two Week Range | 8.3 - 40.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,560,951,000,000 |
| Float Shares | 43,831,327 |
| Forward Eps | -3.17667 |
| Forward P E | -11.4774275 |
| Free Cashflow | 33,024,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 170 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 184,420,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04099 |
| Held Percent Institutions | 1.18659 |
| Implied Shares Outstanding | 59,150,790 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. |
| Long Name | Stoke Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,156,637,696 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_251758622 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -6,885,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,156,637,803 |
| Number Of Analyst Opinions | 10 |
| Open | 37.28 |
| Operating Cashflow | 45,585,000 |
| Operating Margins | -43.822403 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 781 430 8200 |
| Pre Market Change | 0.13999939 |
| Pre Market Change Percent | 0.38398078 |
| Pre Market Price | 36.6 |
| Pre Market Time | 1,776,775,413 |
| Previous Close | 37.27 |
| Price Eps Current Year | -10.825416 |
| Price Hint | 2 |
| Price To Book | 6.0949516 |
| Price To Sales Trailing12 Months | 11.694164 |
| Profit Margins | -0.03733 |
| Quick Ratio | 5.055 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.08333 |
| Region | US |
| Regular Market Change | -0.810001 |
| Regular Market Change Percent | -2.17333 |
| Regular Market Day High | 37.28 |
| Regular Market Day Low | 35.86 |
| Regular Market Day Range | 35.86 - 37.28 |
| Regular Market Open | 37.28 |
| Regular Market Previous Close | 37.27 |
| Regular Market Price | 36.46 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 632,100 |
| Return On Assets | -0.0373 |
| Return On Equity | -0.02368 |
| Revenue Growth | -0.938 |
| Revenue Per Share | 3.114 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 59,150,790 |
| Shares Percent Shares Out | 0.2167 |
| Shares Short | 12,818,891 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 12,402,507 |
| Short Name | Stoke Therapeutics, Inc. |
| Short Percent Of Float | 0.258 |
| Short Ratio | 13.35 |
| Source Interval | 15 |
| State | MA |
| Symbol | STOK |
| Target High Price | 60.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 45.1 |
| Target Median Price | 40.0 |
| Total Cash | 284,670,016 |
| Total Cash Per Share | 4.813 |
| Total Debt | 4,148,000 |
| Total Revenue | 184,420,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 27.24525 |
| Two Hundred Day Average Change | 9.214748 |
| Two Hundred Day Average Change Percent | 0.33821484 |
| Type Disp | Equity |
| Volume | 632,100 |
| Website | https://www.stoketherapeutics.com |
| Zip | 1,730 |